Dr. Besse on the Combination of Treatments for NSCLC

Benjamin Besse, MD
Published: Tuesday, Sep 19, 2017



Benjamin Besse, MD, Institut Gustave Roussy, Villejuif, Paris Sud University, discusses the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) for patients with non–small cell lung cancer.

One percent of patients with NSCLC have the BRAF V600E mutation. This mutation is highly predictive of the combination of dabrafenib and trametinib. Both have been proven to be highly effective in pretreated patients with NSCLC with a response rate of 60% and a progression-free survival of 10 months.

It is a potent combination that has the potential to be the standard of care. These drugs alone are quite toxic but together the toxicity is much less, explains Besse.
 


Benjamin Besse, MD, Institut Gustave Roussy, Villejuif, Paris Sud University, discusses the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) for patients with non–small cell lung cancer.

One percent of patients with NSCLC have the BRAF V600E mutation. This mutation is highly predictive of the combination of dabrafenib and trametinib. Both have been proven to be highly effective in pretreated patients with NSCLC with a response rate of 60% and a progression-free survival of 10 months.

It is a potent combination that has the potential to be the standard of care. These drugs alone are quite toxic but together the toxicity is much less, explains Besse.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x